Published in Lancet on September 10, 2011
Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. PLoS One (2014) 1.23
Overtreatment of COPD with inhaled corticosteroids--implications for safety and costs: cross-sectional observational study. PLoS One (2013) 1.18
COPD and disease-specific health status in a working population. Respir Res (2013) 1.00
Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines. Basic Clin Pharmacol Toxicol (2015) 0.97
Trends in management and outcomes of COPD patients in primary care, 2000-2009: a retrospective cohort study. NPJ Prim Care Respir Med (2014) 0.94
Development and validation of a model to predict the 10-year risk of general practitioner-recorded COPD. NPJ Prim Care Respir Med (2014) 0.93
Anti-inflammatory role of the cAMP effectors Epac and PKA: implications in chronic obstructive pulmonary disease. PLoS One (2012) 0.90
RECODE: design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary care. BMC Pulm Med (2013) 0.87
Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care (2013) 0.87
Frequent utilization of the emergency department for acute exacerbation of chronic obstructive pulmonary disease. Respir Res (2014) 0.86
Temporal trends in hospitalization rates for older adults with chronic obstructive pulmonary disease. Am J Med (2013) 0.85
β-Adrenoceptor blockers and pulmonary function in the general population: the Rotterdam Study. Br J Clin Pharmacol (2014) 0.82
Predictors of treatment with antibiotics and systemic corticosteroids for acute exacerbations of asthma and chronic obstructive pulmonary disease in primary care. BMC Fam Pract (2015) 0.79
Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs. Biomark Insights (2016) 0.76
Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial. PLoS One (2015) 0.75
Pragmatic research and outcomes in asthma and COPD. Pragmat Obs Res (2012) 0.75
Integral Health Status-Based Cluster Analysis in Moderate-Severe COPD Patients Identifies Three Clinical Phenotypes: Relevant for Treatment As Usual and Pulmonary Rehabilitation. Int J Behav Med (2017) 0.75
Misspecification of at-risk periods and distributional assumptions in estimating COPD exacerbation rates: The resultant bias in treatment effect estimation. Pharm Stat (2016) 0.75
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 4.87
Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 4.73
Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med (2012) 3.09
Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 2.80
Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med (2008) 2.66
Airway and systemic inflammation and decline in lung function in patients with COPD. Chest (2005) 2.59
Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. BMJ (2004) 2.39
Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med (2009) 2.17
Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest (2009) 2.16
Use and utility of a 24-hour Telephone Support Service for 'high risk' patients with COPD. Prim Care Respir J (2010) 2.14
Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest (2006) 2.06
Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med (2014) 2.00
Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 1.90
Exacerbation rate, health status and mortality in COPD--a review of potential interventions. Int J Chron Obstruct Pulmon Dis (2009) 1.85
Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 1.85
Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.77
Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2005) 1.75
Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 1.73
Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. Respir Med (2008) 1.68
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT). Eur Respir J (2013) 1.62
Non-invasive positive pressure ventilation for treatment of respiratory failure due to severe acute exacerbations of asthma. Cochrane Database Syst Rev (2012) 1.60
Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax (2012) 1.42
Outdoor air pollution and respiratory health in patients with COPD. Thorax (2011) 1.42
Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.40
IL-1α/IL-1R1 expression in chronic obstructive pulmonary disease and mechanistic relevance to smoke-induced neutrophilia in mice. PLoS One (2011) 1.37
Time course and pattern of COPD exacerbation onset. Thorax (2011) 1.30
The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med (2012) 1.26
Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. Pediatr Infect Dis J (2008) 1.26
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res (2010) 1.14
Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2012) 1.10
Factors associated with change in exacerbation frequency in COPD. Respir Res (2013) 1.08
Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest (2005) 1.07
Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. BMC Med (2009) 1.02
Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest (2009) 1.01
Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study. BMC Pulm Med (2010) 0.99
Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res (2007) 0.98
Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology. COPD (2007) 0.95
Viral infections in obstructive airway diseases. Curr Opin Pulm Med (2003) 0.93
25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease. BMC Pulm Med (2012) 0.93
Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med (2014) 0.92
Upper airway symptoms and quality of life in chronic obstructive pulmonary disease (COPD). Respir Med (2004) 0.92
Reduced lung-cancer mortality with CT screening. N Engl J Med (2011) 0.89
Natural history of successive COPD exacerbations. Thorax (2012) 0.87
Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease. Respir Res (2014) 0.86
Stakeholder involvement: how to do it right: article 9 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc (2012) 0.86
The potential value of biomarkers in diagnosis and staging of COPD and exacerbations. Semin Respir Crit Care Med (2010) 0.84
Use of long-term antibiotic treatment in COPD patients in the UK: a retrospective cohort study. Prim Care Respir J (2013) 0.84
The biology of a chronic obstructive pulmonary disease exacerbation. Clin Chest Med (2007) 0.84
Relationship between chronic nasal and respiratory symptoms in patients with COPD. Respir Med (2003) 0.84
Daily activity during stability and exacerbation of chronic obstructive pulmonary disease. BMC Pulm Med (2014) 0.83
Deprivation, winter season, and COPD exacerbations. Prim Care Respir J (2013) 0.81
Choice of bronchodilator therapy for patients with COPD. N Engl J Med (2011) 0.81
Detrended fluctuation analysis of peak expiratory flow and exacerbation frequency in COPD. Eur Respir J (2012) 0.80
Exacerbation of chronic obstructive pulmonary disease: pan-airway and systemic inflammatory indices. Proc Am Thorac Soc (2006) 0.79
A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. Eur Respir J (2012) 0.78
Acute exacerbations of COPD: the challenge is early treatment. COPD (2009) 0.78
Antibiotics at COPD exacerbations: the debate continues. Thorax (2008) 0.78
Nasal symptoms, airway obstruction and disease severity in chronic obstructive pulmonary disease. Clin Physiol Funct Imaging (2006) 0.78
Airway and systemic inflammation and decline in lung function in patients with COPD. 2005. Chest (2009) 0.77
Chronic cough in chronic obstructive pulmonary disease: time for listening? Am J Respir Crit Care Med (2013) 0.76
Heliox in chronic obstructive pulmonary disease: lightening the airflow. Am J Respir Crit Care Med (2006) 0.76
Response. Chest (2014) 0.75
Indacaterol-Glycopyrronium for COPD. N Engl J Med (2016) 0.75
Exacerbation frequency and FEV1 decline of COPD: is it geographic? Eur Respir J (2014) 0.75
Mechanism of statin-associated mortality reduction in COPD. Chest (2007) 0.75
Winter forecasting of COPD exacerbations. Prim Care Respir J (2011) 0.75
ABC of chronic obstructive pulmonary disease. Acute exacerbations. BMJ (2006) 0.75
The CODEX index: a collection or digest of laws: a code. Chest (2014) 0.75
Prednisone for chronic obstructive pulmonary disease. N Engl J Med (2003) 0.75
Dose response of continuous positive airway pressure on nasal symptoms, obstruction and inflammation in vivo and in vitro. Eur Respir J (2012) 0.75
Intersession repeatability of a novel nasal lavage technique. Transl Res (2011) 0.75
Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2017) 0.75
The role of the phosphodiesterase-4 inhibitor, roflumilast, in chronic obstructive pulmonary disease. Pol Arch Med Wewn (2010) 0.75